6 results on '"Mika Nakama"'
Search Results
2. A carbapenem-resistant clinical isolate of Aeromonas hydrophila in Japan harbouring an acquired gene encoding GES-24 β-lactamase
- Author
-
Tomomi Hishinuma, Yusuke Sawachi, Rei Takaesu, Mika Nakama, Tatsuya Tada, Teruo Kirikae, Kohei Uechi, Jiro Fujita, and Isamu Nakasone
- Subjects
DNA, Bacterial ,0301 basic medicine ,Microbiology (medical) ,Imipenem ,030106 microbiology ,Microbial Sensitivity Tests ,Microbiology ,Meropenem ,beta-Lactamases ,law.invention ,03 medical and health sciences ,Bacterial Proteins ,Japan ,law ,Drug Resistance, Multiple, Bacterial ,polycyclic compounds ,medicine ,Bile ,Humans ,Gene ,Aged, 80 and over ,chemistry.chemical_classification ,biology ,Carbapenem resistant ,Sequence Analysis, DNA ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,biology.organism_classification ,Aeromonas hydrophila ,Anti-Bacterial Agents ,Hospitalization ,Enzyme ,Carbapenems ,chemistry ,Aeromonas ,Genes, Bacterial ,Recombinant DNA ,bacteria ,Female ,Gram-Negative Bacterial Infections ,Genome, Bacterial ,medicine.drug - Abstract
Several species of Aeromonas produce the enzyme CphA metallo-β-lactamase. This study describes an isolate of Aeromonas hydrophila harbouring an acquired gene encoding the carbapenemase GES-24. This isolate was obtained from an inpatient in Okinawa, Japan, with no apparent record of travelling overseas. The minimum inhibitory concentrations of carbapenems against this isolate were 8 µg ml−1 for imipenem and 16 µg ml−1 for meropenem. Recombinant GES-24 hydrolyzed all of the tested β-lactams, including imipenem and meropenem. The genomic environment surrounding bla GES-24 was intI1-bla GES-24 -aac(6′)-IIc-qacEdelta1-sulI-orfX-tetR-tetE. This is the first report of A. hydrophila producing a GES-type carbapenemase.
- Published
- 2018
- Full Text
- View/download PDF
3. Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study
- Author
-
Makoto Nakamura, Kuniko Yokote, Hidetaka Kitazono, Yasuaki Tagashira, Kimberly A. Reske, Sayuri Morita, Kayoko Toimoto, Daisuke Suzuki, Tatsuyuki Watanabe, Takuya Watanabe, Hideaki Kato, Nobuaki Mori, Erik R. Dubberke, Akiko Higuchi, Takao Toyokawa, Fumi Masumoto, Cedric Mahé, Kei Moriya, Hitoshi Honda, Tetsuya Kikuchi, Tatsuya Bando, Saeko Kashiwagura, Kei Kasahara, Margaret A. Olsen, Junko Ogawa, Hisashi Kume, Yousuke Shimizu, Katsuyuki Kojima, Hideaki Ishikawa, Tadashi Fukuda, Hideo Morikawa, Kayoko Tadera, Izumi Yokomaku, Mitsutoshi Senoh, Seigo Kitada, Hiroko Horiuchi, Hiroko Miyazato, Haruko Saito, Masahisa Honda, Mika Nakama, Hiroshi Chiba, Haru Kato, Harumi Tominaga, Jun-ichi Yoshida, Ichiro Yoshikawa, Yasuhiro Norisue, Saori Ishiguro, and Naoto Hosokawa
- Subjects
medicine.medical_specialty ,genetic structures ,Erythromycin ,Microbial Sensitivity Tests ,Ribotyping ,Microbiology ,03 medical and health sciences ,Japan ,Internal medicine ,medicine ,Humans ,Public Health Surveillance ,Geography, Medical ,Prospective cohort study ,Retrospective Studies ,030304 developmental biology ,0303 health sciences ,Clostridioides difficile ,030306 microbiology ,business.industry ,Incidence ,Incidence (epidemiology) ,Clindamycin ,Retrospective cohort study ,Clostridium difficile ,Gatifloxacin ,Anti-Bacterial Agents ,Molecular Typing ,Diarrhea ,Infectious Diseases ,Clostridium Infections ,medicine.symptom ,business ,medicine.drug - Abstract
Clostridioides (Clostridium) difficile is the leading cause of healthcare-associated infectious diarrhea in the developed world. Retrospective studies have shown a lower incidence of C. difficile infection (CDI) in Japan than in Europe or North America. Prospective studies are needed to determine if this is due lack of testing for C. difficile or a true difference in CDI epidemiology. A prospective cohort study of CDI was conducted from May 2014 to May 2015 at 12 medical facilities (20 wards) in Japan. Patients with at least three diarrheal bowel movements (Bristol stool grade 6–7) in the preceding 24 h were enrolled. CDI was defined by positive result on enzyme immunoassay for toxins A/B, nucleic acid amplification test for the toxin B gene or toxigenic culture. C. difficile isolates were subjected to PCR-ribotyping (RT), slpA-sequence typing (slpA-ST), and antimicrobial susceptibility testing. The overall incidence of CDI was 7.4/10,000 patient-days (PD). The incidence was highest in the five ICU wards (22.2 CDI/10,000 PD; range: 13.9–75.5/10,000 PD). The testing frequency and CDI incidence rate were highly correlated (R2 = 0.91). Of the 146 isolates, RT018/018″ was dominant (29%), followed by types 014 (23%), 002 (12%), and 369 (11%). Among the 15 non-ICU wards, two had high CDI incidence rates (13.0 and 15.9 CDI/10,000 PD), with clusters of RT018/slpA-ST smz-02 and 018”/smz-01, respectively. Three non-RT027 or 078 binary toxin-positive isolates were found. All RT018/018” isolates were resistant to moxifloxacin, gatifloxacin, clindamycin, and erythromycin. This study identified a higher CDI incidence in Japanese hospitals than previously reported by actively identifying and testing patients with clinically significant diarrhea. This suggests numerous patients with CDI are being overlooked due to inadequate diagnostic testing in Japan.
- Published
- 2019
- Full Text
- View/download PDF
4. Performance of laboratory tests for detection for Clostridioides difficile: A multicenter prospective study in Japan
- Author
-
Takuya Watanabe, Hisashi Kume, Hideaki Kato, Kimberly A. Reske, Sayuri Morita, Hitoshi Honda, Cedric Mahé, Kei Moriya, Daisuke Suzuki, Kei Kasahara, Katsuyuki Kojima, Seigo Kitada, Tatsuya Bando, Erik R. Dubberke, Hideo Morikawa, Yasuaki Tagashira, Naoto Hosokawa, Haruko Saito, Kayoko Tadera, Masahisa Honda, Haru Kato, Harumi Tominaga, Makoto Nakamura, Kuniko Yokote, Akiko Higuchi, Tatsuyuki Watanabe, Kayoko Toimoto, Saeko Kashiwagura, Yasuhiro Norisue, Tadashi Fukuda, Ichiro Yoshikawa, Hideaki Ishikawa, Mika Nakama, Yousuke Shimizu, Tetsuya Kikuchi, Saori Ishiguro, Junko Ogawa, Hiroshi Chiba, Hiroko Miyazato, Hiroko Horiuchi, Jun-ichi Yoshida, Hidetaka Kitazono, Nobuaki Mori, Takao Toyokawa, Fumi Masumoto, Izumi Yokomaku, Mitsutoshi Senoh, and Margaret A. Olsen
- Subjects
Male ,medicine.medical_specialty ,Bacterial Toxins ,Clostridium difficile toxin B ,Polymerase Chain Reaction ,Ribotyping ,Sensitivity and Specificity ,Microbiology ,Gastroenterology ,03 medical and health sciences ,Japan ,Internal medicine ,medicine ,Humans ,In patient ,Prospective Studies ,Prospective cohort study ,030304 developmental biology ,Bacteriological Techniques ,0303 health sciences ,Clostridioides difficile ,030306 microbiology ,business.industry ,Gold standard (test) ,Predictive value ,Diarrhea ,Infectious Diseases ,Clostridium Infections ,Female ,Enzyme immunoassays ,medicine.symptom ,business ,Clostridioides - Abstract
Background The optimal and practical laboratory diagnostic approach for detection of Clostridioides difficile to aid in the diagnosis of C. difficile infection (CDI) is controversial. A two-step algorithm with initial detection of glutamate dehydrogenase (GDH) or nucleic acid amplification test (NAAT) alone are recommended as a predominant method for C. difficile detection in developed countries. The aim of this study was to compare the performance of enzyme immunoassays (EIA) detecting toxins A and B, NAAT detecting the toxin B gene, and GDH compared to toxigenic culture (TC) for C. difficile as the gold standard, in patients prospectively and actively assessed with clinically significant diarrhea in 12 medical facilities in Japan. Methods A total of 650 stool specimens were collected from 566 patients with at least three diarrheal bowel movements (Bristol stool grade 6–7) in the preceding 24 h. EIA and GDH were performed at each hospital, and NAAT and toxigenic C. difficile culture with enriched media were performed at the National Institute of Infectious Diseases. All C. difficile isolates recovered were analyzed by PCR-ribotyping. Results Compared to TC, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of EIA were 41%, 96%, 75% and 84%, respectively, and for NAAT were 74%, 98%, 91%, and 92%, respectively. In 439 specimens tested with GDH, the sensitivity, specificity, PPV, and NPV were 73%, 87%, 65%, and 91%, and for an algorithm (GDH plus toxin EIA, arbitrated by NAAT) were 71%, 96%, 85%, and 91%, respectively. Among 157 isolates recovered, 75% of isolates corresponded to one of PCR-ribotypes (RTs) 002, 014, 018/018”, and 369; RT027 was not isolated. No clear differences in the sensitivities of any of EIA, NAAT and GDH for four predominant RTs were found. Conclusion The analytical sensitivities of NAAT and GDH-algorithm to detect toxigenic C. difficile in this study were lower than most previous reports. This study also found low PPV of EIAs. The optimal method to detect C. difficile or its toxins to assist in the diagnosis of CDI needs further investigation.
- Published
- 2019
- Full Text
- View/download PDF
5. A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies
- Author
-
Hirohisa Nakamae, Hiroshi Okamura, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Mika Nakamae, Mitsutaka Nishimoto, Yosuke Makuuchi, Masatomo Kuno, Naonori Harada, Teruhito Takakuwa, and Masayuki Hino
- Subjects
Medicine - Abstract
The optimal dose of posttransplant cyclophosphamide (PTCy) for use in patients undergoing HLA-haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (PTCy-haplo) has not been sufficiently examined. This study evaluates the safety and efficacy of HLA-haploidentical hematopoietic cell transplantation with a reduced dose of PTCy for patients with a poor prognosis or those with refractory hematological malignancies. We conducted a prospective clinical study of PTCy-haplo with peripheral blood stem cells (PBSCs) using a modified PTCy dosage regimen consisting of 50 mg/kg on day 3 posttransplantation and a reduced dose of 25 mg/kg on day 4. The cumulative incidences of grades II to III and IV acute graft-versus-host disease (GVHD) at day 100 posttransplantation were 30% and 0%, respectively. The cumulative incidence of moderate-to-severe chronic GVHD after transplantation was 7.0%. The cumulative incidence of nonrelapse mortality at 1 year posttransplantation was 6.1%. Overall survival (OS) at 1 year was 66%. In addition, the restricted cubic-spline Cox regression analysis showed nonlinear relationship between the number of infused CD34 + cells and CD3 + cells, and OS. A graft composition of >4.54 × 10 6 /kg CD34 + cells and >1.85 × 10 8 /kg but ≤3.70 × 10 8 /kg CD3 + cells was significantly associated with better survival, irrespective of the disease status (hazard ratio, 0.13; 95% confidence interval, 0.04–0.41; P < 0.001). These results suggest that PTCy-haplo with PBSCs using a de-escalated dose of 50 mg/kg on day 3 and 25 mg/kg on day 4 posttransplantation is a feasible option.
- Published
- 2022
- Full Text
- View/download PDF
6. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy
- Author
-
Hiroshi Okamura, Hirohisa Nakamae, Takero Shindo, Katsuki Ohtani, Yoshihiko Hidaka, Yasufumi Ohtsuka, Yosuke Makuuchi, Masatomo Kuno, Teruhito Takakuwa, Naonori Harada, Mitsutaka Nishimoto, Yasuhiro Nakashima, Hideo Koh, Asao Hirose, Mika Nakamae, Nobutaka Wakamiya, Masayuki Hino, and Norimitsu Inoue
- Subjects
allogeneic hematopoietic stem cell transplantation ,transplantation associated-thrombotic microangiopathy ,complement ,alternative pathway ,Ba ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous reports suggest that TA-TMA is caused by complement activation by complement-related genetic variants; however, this needs to be verified, especially in adults. Here, we performed a nested case-control study of allo-HSCT-treated adults at a single center. Fifteen TA-TMA patients and 15 non-TA-TMA patients, matched according to the propensity score, were enrolled. Based on a previous report showing an association between complement-related genes and development of TA-TMA, we first sequenced these 17 genes. Both cohorts harbored several genetic variants with rare allele frequencies; however, there was no difference in the percentage of patients in the TA-TMA and non-TA-TMA groups with the rare variants, or in the average number of rare variants per patient. Second, we measured plasma concentrations of complement proteins. Notably, levels of Ba protein on Day 7 following allo-HSCT were abnormally and significantly higher in TA-TMA than in non-TA-TMA cases, suggesting that complement activation via the alternative pathway contributes to TA-TMA. All other parameters, including soluble C5b-9, on Day 7 were similar between the groups. The levels of C3, C4, CH50, and complement factors H and I in the TA-TMA group after Day 28 were significantly lower than those in the non-TA-TMA group. Complement-related genetic variants did not predict TA-TMA development. By contrast, abnormally high levels of Ba on Day 7 did predict development of TA-TMA and non-relapse mortality. Thus, Ba levels on Day 7 after allo-HSCT are a sensitive and prognostic biomarker of TA-TMA.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.